SG70958A1 - Hydroxymethyl (mrthylenecyclopentyl) purines and pyrimidines - Google Patents
Hydroxymethyl (mrthylenecyclopentyl) purines and pyrimidinesInfo
- Publication number
- SG70958A1 SG70958A1 SG1996002080A SG1996002080A SG70958A1 SG 70958 A1 SG70958 A1 SG 70958A1 SG 1996002080 A SG1996002080 A SG 1996002080A SG 1996002080 A SG1996002080 A SG 1996002080A SG 70958 A1 SG70958 A1 SG 70958A1
- Authority
- SG
- Singapore
- Prior art keywords
- mrthylenecyclopentyl
- purines
- pyrimidines
- hydroxymethyl
- chem
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/52—Two oxygen atoms
- C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/52—Two oxygen atoms
- C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
- C07D239/545—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/553—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms with halogen atoms or nitro radicals directly attached to ring carbon atoms, e.g. fluorouracil
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Oncology (AREA)
- Animal Behavior & Ethology (AREA)
- Communicable Diseases (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Virology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Steroid Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Plural Heterocyclic Compounds (AREA)
- Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
- Tires In General (AREA)
- Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US59956890A | 1990-10-18 | 1990-10-18 |
Publications (1)
Publication Number | Publication Date |
---|---|
SG70958A1 true SG70958A1 (en) | 2000-03-21 |
Family
ID=24400159
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG1996002080A SG70958A1 (en) | 1990-10-18 | 1991-10-16 | Hydroxymethyl (mrthylenecyclopentyl) purines and pyrimidines |
Country Status (28)
Country | Link |
---|---|
US (1) | US5206244A (fr) |
EP (1) | EP0481754B1 (fr) |
JP (1) | JP2994117B2 (fr) |
KR (1) | KR0160523B1 (fr) |
CN (1) | CN1030916C (fr) |
AT (1) | ATE157095T1 (fr) |
AU (1) | AU634423B2 (fr) |
BR (1) | BR1100846A (fr) |
CA (1) | CA2053339C (fr) |
CY (2) | CY2063B1 (fr) |
DE (3) | DE69127336T2 (fr) |
DK (1) | DK0481754T3 (fr) |
ES (1) | ES2104673T3 (fr) |
FI (1) | FI109905B (fr) |
GR (1) | GR3025395T3 (fr) |
HK (1) | HK1001343A1 (fr) |
HU (1) | HU213207B (fr) |
IE (1) | IE913451A1 (fr) |
IL (1) | IL99755A (fr) |
LU (1) | LU91275I2 (fr) |
NL (1) | NL300241I1 (fr) |
NO (2) | NO179906C (fr) |
NZ (1) | NZ240053A (fr) |
PL (1) | PL169403B1 (fr) |
PT (1) | PT99281B (fr) |
RU (1) | RU2037496C1 (fr) |
SG (1) | SG70958A1 (fr) |
ZA (1) | ZA917894B (fr) |
Families Citing this family (62)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0630897A3 (fr) * | 1993-06-25 | 1995-03-01 | Bristol Myers Squibb Co | 3-Hydroxy-4-hydroxyméthyl-2-methylène-cyclopentyl purines et pyrimidines. |
WO1996001834A1 (fr) * | 1994-07-12 | 1996-01-25 | Yamasa Corporation | 2'-desoxy-2'-(methylidene substitue ou non substitue)-4'-thionucleoside |
AU4303996A (en) * | 1994-12-19 | 1996-07-10 | Novartis Ag | 6'-substituted carbocyclic nucleosides |
GB9520363D0 (en) * | 1995-10-05 | 1995-12-06 | Chiroscience Ltd | Compounds |
AU4090697A (en) * | 1996-09-03 | 1998-03-26 | Bristol-Myers Squibb Company | Improved process for preparing the antiviral agent {1s-(1alpha, 3alpha, 4beta)}-2-amino-1,9-dihydro-9-{4-hydroxy-3-(hydroxymethyl)-2 -methylenecyclopentyl}-6h-purin-6-one |
US6444652B1 (en) | 1998-08-10 | 2002-09-03 | Novirio Pharmaceuticals Limited | β-L-2'-deoxy-nucleosides for the treatment of hepatitis B |
DK2415776T3 (en) * | 1998-08-10 | 2016-07-04 | Novartis Ag | Beta-L-2'-deoxy nucleosides for the treatment of Hepatitis B |
US6432966B2 (en) | 1999-10-29 | 2002-08-13 | Smithkline Beecham Corporation | Antiviral combinations |
JP5140222B2 (ja) * | 2000-02-29 | 2013-02-06 | ブリストル−マイヤーズ スクイブ カンパニー | 低用量エンテカビル製剤およびその使用 |
CN101385732A (zh) * | 2000-02-29 | 2009-03-18 | 布里斯托尔-迈尔斯斯奎布公司 | 低剂量艾替开韦制剂及其应用 |
US20020056123A1 (en) * | 2000-03-09 | 2002-05-09 | Gad Liwerant | Sharing a streaming video |
TWI275392B (en) * | 2002-04-08 | 2007-03-11 | Bristol Myers Squibb Co | Low dose liquid entecavir formulations and use |
US7153691B2 (en) * | 2002-11-13 | 2006-12-26 | G6 Science Corp. | Method of identifying and assessing DNA euchromatin in biological cells for detecting disease, monitoring wellness, assessing bio-activity, and screening pharmacological agents |
IN2012DN00605A (fr) * | 2002-12-11 | 2015-06-12 | Bristol Mayers Squibb Company | |
TW200540175A (en) * | 2004-06-04 | 2005-12-16 | Bristol Myers Squibb Co | Process for the preparation of entecavir and novel intermediates thereof via carbon-silicon oxidation |
US7511139B2 (en) * | 2004-06-04 | 2009-03-31 | Bristol-Myers Squibb Company | Process for the preparation of entecavir and novel intermediates thereof via carbon-silicon oxidation |
CN100379736C (zh) * | 2005-05-13 | 2008-04-09 | 上海仲夏化学有限公司 | 恩替卡韦的制备方法 |
CN1699366A (zh) * | 2005-06-03 | 2005-11-23 | 北京市典范科技有限责任公司 | 嘌呤衍生物 |
CN1907987B (zh) * | 2005-08-03 | 2010-05-05 | 江苏正大天晴药业股份有限公司 | 恩地卡韦酸加成盐及其制备方法和用途 |
US20070060599A1 (en) * | 2005-09-09 | 2007-03-15 | Dimarco John D | Crystalline forms of [1S-(1alpha, 3alpha, 4beta)]-2-amino-1,9-dihydro-9-[4-hydroxy-3-(hydroxymethyl)-2-methylenecyclopentyl]-6H-purin-6-one |
CN101016299B (zh) * | 2006-02-09 | 2010-05-12 | 北京典范科技有限责任公司 | 制备嘌呤衍生物的新方法 |
CN101130542B (zh) * | 2006-08-24 | 2010-08-04 | 江苏正大天晴药业股份有限公司 | 抗病毒核苷类似物的合成方法 |
CN101210015B (zh) * | 2006-12-26 | 2010-09-22 | 上海国创医药有限公司 | 一种乙肝治疗药物恩替卡韦的制备方法 |
CN101245068A (zh) * | 2007-02-14 | 2008-08-20 | 浙江医药股份有限公司新昌制药厂 | 结晶型态的恩替卡韦及其制备方法和其药物组合物及用途 |
CN101074217B (zh) * | 2007-04-04 | 2010-11-24 | 北京精华***医药科技有限公司 | 通过制备色谱分离得到高纯度恩替卡韦关键中间体的方法 |
EP2159224B1 (fr) | 2007-06-18 | 2012-08-01 | Sunshine Lake Pharma Co., Ltd | Thiazolyl-dihydropyrimidines à substitution bromo-phényle |
US20090076038A1 (en) * | 2007-09-14 | 2009-03-19 | Protia, Llc | Deuterium-enriched entecavir |
US8173621B2 (en) | 2008-06-11 | 2012-05-08 | Gilead Pharmasset Llc | Nucleoside cyclicphosphates |
TW201010692A (en) | 2008-06-19 | 2010-03-16 | Public Univ Corp Nagoya City Univ | Pharmaceutical composition for treatment or prevention of hbv infection |
EA019295B1 (ru) | 2008-12-23 | 2014-02-28 | Джилид Фармассет, Ллс. | Соединения пуриновых нуклеозидов и способ их получения |
US8551973B2 (en) * | 2008-12-23 | 2013-10-08 | Gilead Pharmasset Llc | Nucleoside analogs |
EP2376088B1 (fr) | 2008-12-23 | 2017-02-22 | Gilead Pharmasset LLC | Phosphoramidates de nucléosides de type 2-amino-purine 6-O-substituée |
KR101150254B1 (ko) * | 2008-12-26 | 2012-06-12 | 한미사이언스 주식회사 | 신규 중간체 및 이를 활용한 엔테카비르 제조방법 |
CN101531660B (zh) * | 2009-04-14 | 2012-07-04 | 安徽贝克联合制药有限公司 | 一种恩替卡韦一水合物的工业化生产工艺 |
CA2777018C (fr) * | 2009-10-12 | 2014-04-29 | Hanmi Holdings Co., Ltd. | Nouveau procede de preparation d'entecavir et ses intermediaires |
US9700560B2 (en) * | 2009-11-16 | 2017-07-11 | University Of Georgia Research Foundation, Inc. | 2′-fluoro-6′-methylene carbocyclic nucleosides and methods of treating viral infections |
CN101759698B (zh) * | 2009-12-15 | 2012-01-18 | 上海医药集团股份有限公司 | 一种恩替卡韦的制备方法 |
US8481728B2 (en) * | 2010-02-16 | 2013-07-09 | Scinopharm Taiwan, Ltd. | Process for preparing entecavir and its intermediates |
JP2013527145A (ja) | 2010-03-31 | 2013-06-27 | ギリード・ファーマセット・エルエルシー | リン含有活性化剤の立体選択的合成 |
CA2705953C (fr) | 2010-05-31 | 2018-05-01 | Alphora Research Inc. | Synthese de carbanucleoside et composes intermediaires utiles pour la synthese |
EP2474548A1 (fr) | 2010-12-23 | 2012-07-11 | Esteve Química, S.A. | Procédé de préparation d'un médicament antiviral et ses intermédiaires |
EP2508172A1 (fr) | 2011-04-06 | 2012-10-10 | Zentiva, a.s. | Formulations stables et uniformes d'entecavir et procédé de préparation correspondant |
CN102491960A (zh) * | 2011-11-16 | 2012-06-13 | 福建广生堂药业股份有限公司 | 一种合成恩替卡韦的中间体及其制备方法和应用 |
EP2597096A1 (fr) | 2011-11-24 | 2013-05-29 | Esteve Química, S.A. | Procédé de préparation d'entecavir et intermédiaires associés |
CN103304375B (zh) * | 2012-03-12 | 2017-04-12 | 浙江奥翔药业股份有限公司 | 恩替卡韦的合成中间体及其制备方法 |
AU2013257951A1 (en) | 2012-05-11 | 2015-01-22 | Akron Molecules Ag | Use of compounds for the treatment of pain |
CA2889903C (fr) | 2012-10-29 | 2021-03-09 | Manjinder Singh Phull | Analogues de phosphonate antiviraux et leur procede de preparation |
EP2832351A1 (fr) | 2013-07-29 | 2015-02-04 | Sanovel Ilac Sanayi ve Ticaret A.S. | Comprimé multicouche comprenant du tenofovir et de l'entecavir |
WO2015051900A1 (fr) | 2013-10-08 | 2015-04-16 | Pharmathen S.A. | Procédé de préparation d'entécavir au moyen de nouveaux intermédiaires |
KR101640504B1 (ko) * | 2015-04-15 | 2016-07-18 | 동방에프티엘(주) | 엔테카비르 일수화물의 제조방법 |
KR101640503B1 (ko) * | 2015-04-15 | 2016-07-18 | 동방에프티엘(주) | 엔테카비르 일수화물의 개선된 제조방법 |
JP6912100B2 (ja) * | 2016-11-16 | 2021-07-28 | 国立研究開発法人国立国際医療研究センター | 抗ウイルス活性等の生理活性を有するヌクレオシド誘導体 |
CN108203435B (zh) * | 2016-12-16 | 2020-09-04 | 正大天晴药业集团股份有限公司 | 一种利用Boc保护基的恩替卡韦的制备方法 |
CN106749251A (zh) * | 2017-01-17 | 2017-05-31 | 博瑞生物医药泰兴市有限公司 | 一种恩替卡韦中间体的合成与提纯方法 |
KR102197257B1 (ko) * | 2017-10-19 | 2020-12-31 | 단국대학교 천안캠퍼스 산학협력단 | 엔테카비어 지방산 에스테르 유도체 수성현탁액의 안정화 조성물 |
CN109956975B (zh) * | 2017-12-22 | 2020-11-06 | 浙江柏拉阿图医药科技有限公司 | 肝递送恩替卡韦前体药物核苷环磷酸酯化合物及应用 |
CN113544122A (zh) * | 2018-12-12 | 2021-10-22 | 詹森生物制药有限公司 | 作为抗病毒药的环戊基核苷类似物 |
CN113024574B (zh) * | 2019-12-25 | 2024-03-29 | 南通诺泰生物医药技术有限公司 | 一种氧杂二环己烷类化合物的制备方法 |
CN111732589B (zh) * | 2020-06-08 | 2021-07-30 | 王乔 | 一种改进的恩替卡韦中间体合成工艺以及改进的恩替卡韦合成工艺 |
CN112625041A (zh) * | 2020-12-25 | 2021-04-09 | 常州博海威医药科技股份有限公司 | 恩替卡韦的新制备方法以及中间体 |
CN115433188B (zh) * | 2022-09-29 | 2024-07-12 | 苏州东瑞制药有限公司 | 一种恩替卡韦的制备方法 |
CN115819422A (zh) * | 2022-12-13 | 2023-03-21 | 淄博矿业集团有限责任公司 | 恩替卡韦中间体制备新工艺方法及分析方法 |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IN164556B (fr) * | 1986-03-06 | 1989-04-08 | Takeda Chemical Industries Ltd | |
US5063233A (en) * | 1986-11-14 | 1991-11-05 | Ciba-Geigy Corporation | N9 -cyclopentyl-substituted adenine derivatives useful as adenosine receptor agonists |
ATE124702T1 (de) * | 1987-03-19 | 1995-07-15 | Yamasa Shoyu Kk | 2'-alkyliden-pyrimidin-nukleosid-derivate, verfahren zur herstellung und verwendung. |
NZ225906A (en) * | 1987-08-26 | 1990-10-26 | Merrell Dow Pharma | Aristeromycin/adenosine derivatives and pharmaceutical compositions |
US4997925A (en) * | 1987-08-26 | 1991-03-05 | Merrell Dow Pharmaceuticals Inc. | 5'-deoxy-5',5'-dihalo adenosines and purine analogues |
GB8815265D0 (en) * | 1988-06-27 | 1988-08-03 | Wellcome Found | Therapeutic nucleosides |
ATE154359T1 (de) * | 1988-08-25 | 1997-06-15 | Yoshitomi Pharmaceutical | 2'-methylidenpyrimidinnukleosidverbindungen, ihre verwendung und verfahren zu ihrer herstellung |
HU204843B (en) * | 1988-09-27 | 1992-02-28 | Merrell Dow Pharma | Process for producing 2'-halogen-methylidene adenosine derivatives and pharmaceutical compositions comprising same |
GB8916478D0 (en) * | 1989-07-19 | 1989-09-06 | Glaxo Group Ltd | Chemical process |
US5064961A (en) * | 1989-12-18 | 1991-11-12 | E. R. Squibb & Sons, Inc. | Process for preparing an optically active cyclobutane nucleoside |
US5057630A (en) * | 1990-04-06 | 1991-10-15 | Glaxo Inc. | Synthesis of cyclopentene derivatives |
-
1991
- 1991-09-20 US US07/763,033 patent/US5206244A/en not_active Expired - Lifetime
- 1991-10-01 NZ NZ240053A patent/NZ240053A/xx not_active IP Right Cessation
- 1991-10-01 IE IE345191A patent/IE913451A1/en active Protection Beyond IP Right Term
- 1991-10-02 ZA ZA917894A patent/ZA917894B/xx unknown
- 1991-10-04 AU AU85598/91A patent/AU634423B2/en not_active Expired
- 1991-10-11 CA CA002053339A patent/CA2053339C/fr not_active Expired - Lifetime
- 1991-10-15 IL IL9975591A patent/IL99755A/en not_active IP Right Cessation
- 1991-10-16 SG SG1996002080A patent/SG70958A1/en unknown
- 1991-10-16 DE DE69127336T patent/DE69127336T2/de not_active Expired - Lifetime
- 1991-10-16 EP EP91309525A patent/EP0481754B1/fr not_active Expired - Lifetime
- 1991-10-16 ES ES91309525T patent/ES2104673T3/es not_active Expired - Lifetime
- 1991-10-16 AT AT91309525T patent/ATE157095T1/de active
- 1991-10-16 DE DE1991627336 patent/DE122006000069I1/de active Pending
- 1991-10-16 DK DK91309525.3T patent/DK0481754T3/da active
- 1991-10-17 KR KR1019910018259A patent/KR0160523B1/ko not_active IP Right Cessation
- 1991-10-17 RU SU915001946A patent/RU2037496C1/ru active Protection Beyond IP Right Term
- 1991-10-17 HU HU913283A patent/HU213207B/hu active Protection Beyond IP Right Term
- 1991-10-17 NO NO914089A patent/NO179906C/no not_active IP Right Cessation
- 1991-10-18 FI FI914928A patent/FI109905B/fi active Protection Beyond IP Right Term
- 1991-10-18 JP JP3271121A patent/JP2994117B2/ja not_active Expired - Lifetime
- 1991-10-18 PT PT99281A patent/PT99281B/pt not_active IP Right Cessation
- 1991-10-18 CN CN91110831A patent/CN1030916C/zh not_active Expired - Lifetime
- 1991-10-18 PL PL91292101A patent/PL169403B1/pl unknown
-
1997
- 1997-05-12 BR BR1100846-6A patent/BR1100846A/pt active IP Right Grant
- 1997-11-17 GR GR970403039T patent/GR3025395T3/el unknown
-
1998
- 1998-01-19 HK HK98100422A patent/HK1001343A1/xx not_active IP Right Cessation
- 1998-06-12 CY CY9802063A patent/CY2063B1/xx unknown
-
2006
- 2006-08-30 LU LU91275C patent/LU91275I2/fr unknown
- 2006-09-21 NL NL300241C patent/NL300241I1/nl unknown
- 2006-12-05 NO NO2006018C patent/NO2006018I2/no unknown
- 2006-12-22 DE DE200612000069 patent/DE122006000069I2/de active Active
-
2014
- 2014-09-29 CY CY2006008C patent/CY2006008I2/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG70958A1 (en) | Hydroxymethyl (mrthylenecyclopentyl) purines and pyrimidines | |
ES2056096T3 (es) | Purinil-ciclobutanos. | |
NZ228645A (en) | 1,3-dioxolane derivatives substituted in the 5th position by a purine or pyrimidine radical; treatment of viral infections | |
AU616839B2 (en) | Purinyl and pyrimidinyl tetrahydrofurans | |
ZA914894B (en) | Purinyl and pyrimidinyl tetrahydrofurans | |
EP0352013A3 (fr) | Hydroxyméthyl cyclobutylepurines |